| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new war on cancer?
|
Lawler, Mark
|
|
|
26 |
4 |
p. 406-408
|
artikel
|
| 2 |
Call for a global cancer funding collaboration
|
The Lancet Oncology,
|
|
|
26 |
4 |
p. 399
|
artikel
|
| 3 |
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis
|
Dee, Edward Christopher
|
|
|
26 |
4 |
p. 516-528
|
artikel
|
| 4 |
Chemical industry lobbyists will run chemical safety oversight at US EPA
|
Furlow, Bryant
|
|
|
26 |
4 |
p. 416
|
artikel
|
| 5 |
Children and young people with cancer affected by disability benefit delays
|
Gourd, Elizabeth
|
|
|
26 |
4 |
p. 418
|
artikel
|
| 6 |
Correction to Lancet Oncol 2025; 26: 367–77
|
|
|
|
26 |
4 |
p. e186
|
artikel
|
| 7 |
Correction to Lancet Oncol 2024; 25: e205–16
|
|
|
|
26 |
4 |
p. e186
|
artikel
|
| 8 |
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial
|
Dinneen, Eoin
|
|
|
26 |
4 |
p. 447-458
|
artikel
|
| 9 |
EUROPA trial: cost implications of radiotherapy versus endocrine therapy
|
McClelland, Shearwood
|
|
|
26 |
4 |
p. e182
|
artikel
|
| 10 |
EUROPA trial: cost implications of radiotherapy versus endocrine therapy – Authors' reply
|
Meattini, Icro
|
|
|
26 |
4 |
p. e183
|
artikel
|
| 11 |
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
|
Matsubara, Nobuaki
|
|
|
26 |
4 |
p. 470-480
|
artikel
|
| 12 |
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
|
Fay, Andre P
|
|
|
26 |
4 |
p. 481-490
|
artikel
|
| 13 |
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
|
Powles, Thomas
|
|
|
26 |
4 |
p. 491-502
|
artikel
|
| 14 |
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium
|
Kishan, Amar U
|
|
|
26 |
4 |
p. 459-469
|
artikel
|
| 15 |
Innovative, early-phase clinical trials of drug–radiotherapy combinations
|
Levy, Antonin
|
|
|
26 |
4 |
p. e190-e202
|
artikel
|
| 16 |
Integrating dental and oral care in oncology: a crucial step towards comprehensive cancer treatment
|
Vigarios, Emmanuelle
|
|
|
26 |
4 |
p. e184
|
artikel
|
| 17 |
Internationally trained doctors in the USA
|
Devi, Sharmila
|
|
|
26 |
4 |
p. 419
|
artikel
|
| 18 |
Lung cancer treatment compromised by delayed genomic test results
|
Gourd, Elizabeth
|
|
|
26 |
4 |
p. 420
|
artikel
|
| 19 |
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting
|
De Meerleer, Gert
|
|
|
26 |
4 |
p. 403-404
|
artikel
|
| 20 |
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial
|
van der Wilk, Berend J
|
|
|
26 |
4 |
p. 425-436
|
artikel
|
| 21 |
New agreement aims to eliminate cervical cancer across the Americas
|
Gruber, Karl
|
|
|
26 |
4 |
p. 414
|
artikel
|
| 22 |
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis
|
Pearson, Andrew D J
|
|
|
26 |
4 |
p. e214-e224
|
artikel
|
| 23 |
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
|
Graham, Charlotte E
|
|
|
26 |
4 |
p. e203-e213
|
artikel
|
| 24 |
Non-surgical approach to operable oesophageal cancer: is it prime time yet?
|
Mukherjee, Somnath
|
|
|
26 |
4 |
p. 400-401
|
artikel
|
| 25 |
PARP inhibitors for prostate cancer: for whom and when?
|
Cooperberg, Matthew R
|
|
|
26 |
4 |
p. 404-406
|
artikel
|
| 26 |
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
|
Van Gorp, Toon
|
|
|
26 |
4 |
p. 503-515
|
artikel
|
| 27 |
Projected global rise in breast cancer incidence and mortality by 2050
|
Devi, Sharmila
|
|
|
26 |
4 |
p. 417
|
artikel
|
| 28 |
Proposed US bill to reform Medicare payments for radiotherapy
|
Gruber, Karl
|
|
|
26 |
4 |
p. e187
|
artikel
|
| 29 |
Re-evaluating anxiety levels and participant characteristics in PATHFINDER
|
Xiang, Ze
|
|
|
26 |
4 |
p. e185
|
artikel
|
| 30 |
Rwanda makes great strides in cancer control and treatment
|
Burki, Talha
|
|
|
26 |
4 |
p. e188
|
artikel
|
| 31 |
Sexual health and reproductive toxicity from cancer therapies
|
Benjamin, David J
|
|
|
26 |
4 |
p. 408-410
|
artikel
|
| 32 |
The impact of armed conflict on global patterns of childhood cancer
|
Espinoza, Pamela
|
|
|
26 |
4 |
p. 421-424
|
artikel
|
| 33 |
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales
|
Aggarwal, Ajay
|
|
|
26 |
4 |
p. e225-e232
|
artikel
|
| 34 |
Thousands in the UK miss cancer screenings due to NHS error
|
Venkatesan, Priya
|
|
|
26 |
4 |
p. e189
|
artikel
|
| 35 |
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
|
Li, Ziming
|
|
|
26 |
4 |
p. 437-446
|
artikel
|
| 36 |
Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC
|
Brueckl, Wolfgang M
|
|
|
26 |
4 |
p. 401-403
|
artikel
|
| 37 |
UK sees almost 30 000 extra cancer deaths each year due to deprivation
|
Kirby, Tony
|
|
|
26 |
4 |
p. 415
|
artikel
|
| 38 |
WHO Classification of Tumours: evolution of a global resource in the molecular era
|
Hodge, Jennelle C
|
|
|
26 |
4 |
p. 410-413
|
artikel
|
Tijdschrift beschrijving